ATNM — Actinium Pharmaceuticals Cashflow Statement
0.000.00%
- $40.87m
- -$32.02m
Annual cashflow statement for Actinium Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -22.2 | -24.8 | -33 | -48.8 | -38.2 |
Depreciation | |||||
Non-Cash Items | 1.25 | 1.69 | 2.79 | 3.84 | 5.29 |
Other Non-Cash Items | |||||
Changes in Working Capital | -1.1 | 1.69 | 38.2 | -3.15 | -0.932 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -21.6 | -20.9 | 8.64 | -47.3 | -33.1 |
Capital Expenditures | -0.253 | -0.133 | -0.366 | -0.153 | -0.011 |
Purchase of Fixed Assets | |||||
Cash from Investing Activities | -0.253 | -0.133 | -0.366 | -0.153 | -0.011 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 76.2 | 35.2 | 23.1 | 14.9 | 29.3 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 54.3 | 14.2 | 31.4 | -32.6 | -3.76 |